1. Home
  2. BCYC vs LAB Comparison

BCYC vs LAB Comparison

Compare BCYC & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

BUY

Current Price

$4.01

Market Cap

291.8M

Sector

Health Care

ML Signal

BUY

Logo Standard BioTools Inc.

LAB

Standard BioTools Inc.

SELL

Current Price

$0.76

Market Cap

271.0M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
BCYC
LAB
Founded
2009
1999
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
291.8M
271.0M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
BCYC
LAB
Price
$4.01
$0.76
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $9.50
N/A
AVG Volume (30 Days)
460.1K
★ 996.5K
Earning Date
10-29-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.54
EPS
N/A
★ 0.26
Revenue
N/A
★ $101,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$2.80
Revenue Growth
★ N/A
N/A
52 Week Low
$3.55
$0.63
52 Week High
$9.16
$1.72

Technical Indicators

Market Signals
Indicator
BCYC
LAB
Relative Strength Index (RSI) 54.35 60.66
Support Level $3.91 $0.78
Resistance Level $4.21 $1.02
Average True Range (ATR) 0.18 0.04
MACD 0.02 0.01
Stochastic Oscillator 84.24 83.11

Price Performance

Historical Comparison
BCYC
LAB

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

About LAB Standard BioTools Inc.

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Share on Social Networks: